Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and resistance-conferring tyrosine kinase domain mutations. While crenolanib monotherapy has demonstrated clinical benefit in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haijiao, Savage, Samantha, Schultz, Anna Reister, Bottomly, Daniel, White, Libbey, Segerdell, Erik, Wilmot, Beth, McWeeney, Shannon K., Eide, Christopher A., Nechiporuk, Tamilla, Carlos, Amy, Henson, Rachel, Lin, Chenwei, Searles, Robert, Ho, Hoang, Lam, Yee Ling, Sweat, Richard, Follit, Courtney, Jain, Vinay, Lind, Evan, Borthakur, Gautam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., Cortes, Jorge, Collins, Robert, Buelow, Daelynn R., Baker, Sharyn D., Druker, Brian J., Tyner, Jeffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335421/
https://www.ncbi.nlm.nih.gov/pubmed/30651561
http://dx.doi.org/10.1038/s41467-018-08263-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335421/
https://www.ncbi.nlm.nih.gov/pubmed/30651561
http://dx.doi.org/10.1038/s41467-018-08263-x

Ejemplares similares